CoChat

A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy

Open access
Van Geest, Rob J, Lesnik-Oberstein, Sarit Y, Tan, H Stevie, Mura, Marco, Goldschmeding, Roel, Van Noorden, Cornelis J F, Klaassen, Ingeborg, Schlingemann, Reinier O · 2012 · British Journal of Ophthalmology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Introduction In proliferative diabetic retinopathy (PDR), vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF) may cause blindness by neovascularisation followed by fibrosis of the retina. It has previously been shown that a shift in the balance between levels of CTGF and VEGF in the eye is associated with this angiofibrotic switch. This study investigated whether anti-VEGF agents induce accelerated fibrosis in patients with PDR, as predicted by this model. Methods CTGF and VEGF levels were measured by ELISA in 52 vitreous samples of PDR patients, of which 24 patients had received intravitreal bevacizumab 1 week to 3 months before vitrectomy, and were correlated with the degree of vitreoretinal fibrosis as determined clinically and intra-operatively. Results CTGF correlated positively, and VEGF correlated negatively with the degree of fibrosis. The CTGF/VEGF ratio was the strongest predictor of fibrosis. Clinically, increased fibrosis was observed after intravitreal bevacizumab. Conclusions These results confirm that the CTGF/VEGF ratio is a strong predictor of vitreoretinal fibrosis in PDR, and show that intravitreal anti-VEGF treatment causes increased fibrosis in PDR patients. These findings provide strong support for the model that the balance of CTGF and VEGF determines the angiofibrotic switch, and identify CTGF as a possible therapeutic target in the clinical management of PDR

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2011-301005

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Vitreous connective tissue growth factor (CTGF) levels (A) and CTGF/log10 (vascular endothelial growth factor; VEGF) ratio (B) per degree of fibrosis of the retina. Filled symbols: proliferative diabetic retinopathy group. Open symbols: bevacizumab group; means of each group are also presented. (A) Vitreous CTGF levels and degree of fibrosis correlated significantly (Spearman's ρ 0.6, p<0.001). (B) The CTGF/log10(VEGF) ratio and degree of fibrosis correlated significantly (Spearman's ρ 0.7, p<0.001).
Figure 1 Vitreous connective tissue growth factor (CTGF) levels (A) and CTGF/log10 (vascular endothelial growth factor; VEGF) ratio (B) per degree of fibrosis of the retina. Filled symbols: proliferative diabetic retinopathy group. Open symbols: bevacizumab group; means of each group are also presented. (A) Vitreous CTGF levels and degree of fibrosis correlated significantly (Spearman's ρ 0.6, p<0.001). (B) The CTGF/log10(VEGF) ratio and degree of fibrosis correlated significantly (Spearman's ρ 0.7, p<0.001).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 141

Metadata

Authors
Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J. F., Klaassen, I., & Schlingemann, R. O.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • University Medical Center Utrecht (NL)
  • Netherlands Institute for Neuroscience (NL)
Corresponding author
Schlingemann, Reinier O
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2012-01-29
Volume
96
Issue
4
Pages
587-590
ISSN
  • 0001-639X (ISSN-L)
  • 0007-1161
  • 1468-2079
OpenAlex
W2132899855
Cited by
141
References
33
Citations by year
2025: 5 · 2024: 9 · 2023: 11 · 2022: 10 · 2021: 9 · 2020: 11 · 2019: 8 · 2018: 16 · 2017: 17 · 2016: 10 · 2015: 9 · 2014: 14 · 2013: 7 · 2012: 5
Type
conference abstract
Language
en
Open access
Licence
cc-by-nc
Locations
  • Acta Ophthalmologica (publishedVersion)
  • British Journal of Ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
Diabetes Fonds
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
Keywords
proliferative diabetic retinopathy, bevacizumab, vascular endothelial growth factor, connective tissue growth factor, vitreoretinal fibrosis, anti-VEGF therapy, vitreous humor, neovascularization, vitrectomy
MeSH terms
Bevacizumab, Diabetic Retinopathy, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Male, Middle Aged, Vitrectomy, Vitreous Body, Retinal Neovascularization, Disease Progression, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Connective Tissue Growth Factor, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. https://app.cochat.ai/papers/10.1136/bjophthalmol-2011-301005
The paper
Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J. F., Klaassen, I., & Schlingemann, R. O. (2012). A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2011-301005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.